Atorvastatin in pulmonary arterial hypertension (APATH) study

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Statins, including atorvastatin, have demonstrated preventive and attenuating effects on pulmonary hypertension in preclinical animal models.
• Pulmonary hypertension (PH) encompasses conditions like pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), necessitating affordable and effective treatments.

Purpose of the Study:

• To investigate the therapeutic potential of atorvastatin as an accessible treatment option for patients diagnosed with PAH or CTEPH.
• To evaluate the efficacy of atorvastatin in improving clinical outcomes and disease progression in PH patients over a 6-month period.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 220 patients with PAH or CTEPH.
• Participants received either atorvastatin 10 mg daily or a matching placebo, in addition to standard supportive care.
• Key outcome measures included the 6-minute walk distance, pulmonary vascular resistance, cardiac output, and World Health Organization functional class.

Main Results:

• The 6-minute walk distance showed a non-significant decrease in both the atorvastatin (-16.6 m) and placebo (-14.1 m) groups, with a placebo-corrected effect of -2.5 m (p=0.96).
• No significant differences were observed in pulmonary vascular resistance, cardiac output, or World Health Organization functional class between the treatment arms.
• Serum cholesterol levels significantly decreased in the atorvastatin group, but this did not translate to clinical benefit in PH progression.

Conclusions:

• Atorvastatin 10 mg daily administered for 6 months did not demonstrate a beneficial effect on the natural history of pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).
• The findings suggest that atorvastatin, at this dosage and duration, is not an effective treatment for improving clinical outcomes in patients with these forms of pulmonary hypertension.
• Further research may be needed to explore different statin regimens or patient populations, but this study does not support its use for PH treatment.